BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

...dermatology business through its 2009 acquisition of Stiefel Laboratories Inc. for $2.9 billion (see “GSK to Acquire Stiefel”...
BioCentury | Jul 13, 2018
Company News

Dermatitis, psoriasis candidate passed from GSK to Dermavant

...Roivant Sciences GmbH, Basel, Switzerland GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Dermatology Allison Johnson GSK2894512, WBI-1001 GlaxoSmithKline plc Stiefel Laboratories Inc. Roivant...
BioCentury | Jul 12, 2018
Company News

GSK hands off dermatitis, psoriasis candidate to Dermavant

...2012 deal with Welichem Biotech Inc. (Burnaby, B.C.). Dermavant declined to provide details. Allison Johnson GSK2894512, WBI-1001 GlaxoSmithKline plc Stiefel Laboratories Inc. Roivant...
BioCentury | Apr 28, 2017
Clinical News

Serelaxin: Development discontinued

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...
BioCentury | Mar 24, 2017
Clinical News

Serelaxin: Ph III RELAX-AHF-2 data

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...
BioCentury | Apr 4, 2016
Regulation

Looking beyond appearances

...treatments now available to them," noted Jim Lee, VP of global clinical development at the Stiefel Laboratories Inc....
BioCentury | Dec 21, 2015
Company News

GlaxoSmithKline, Almirall deal

...and Mexico under a June 2010 deal with Basilea Pharmaceutica AG (SIX:BSLN, Basel, Switzerland). GSK’s Stiefel Laboratories Inc....
BioCentury | Oct 27, 2015
Company News

Woodford mum on his GSK wish list

...the separation of the company's HIV business ViiV Healthcare, its consumer healthcare business and its Stiefel...
BioCentury | Oct 13, 2014
Clinical News

Arzerra ofatumumab: Phase III started

...GlaxoSmithKline's Stiefel dermatology business began the double-blind, placebo-controlled, international Phase III OPV116910 trial to compare 20...
BioCentury | May 26, 2014
Clinical News

Reasanz serelaxin regulatory update

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...
Items per page:
1 - 10 of 93
BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

...dermatology business through its 2009 acquisition of Stiefel Laboratories Inc. for $2.9 billion (see “GSK to Acquire Stiefel”...
BioCentury | Jul 13, 2018
Company News

Dermatitis, psoriasis candidate passed from GSK to Dermavant

...Roivant Sciences GmbH, Basel, Switzerland GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Dermatology Allison Johnson GSK2894512, WBI-1001 GlaxoSmithKline plc Stiefel Laboratories Inc. Roivant...
BioCentury | Jul 12, 2018
Company News

GSK hands off dermatitis, psoriasis candidate to Dermavant

...2012 deal with Welichem Biotech Inc. (Burnaby, B.C.). Dermavant declined to provide details. Allison Johnson GSK2894512, WBI-1001 GlaxoSmithKline plc Stiefel Laboratories Inc. Roivant...
BioCentury | Apr 28, 2017
Clinical News

Serelaxin: Development discontinued

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...
BioCentury | Mar 24, 2017
Clinical News

Serelaxin: Ph III RELAX-AHF-2 data

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...
BioCentury | Apr 4, 2016
Regulation

Looking beyond appearances

...treatments now available to them," noted Jim Lee, VP of global clinical development at the Stiefel Laboratories Inc....
BioCentury | Dec 21, 2015
Company News

GlaxoSmithKline, Almirall deal

...and Mexico under a June 2010 deal with Basilea Pharmaceutica AG (SIX:BSLN, Basel, Switzerland). GSK’s Stiefel Laboratories Inc....
BioCentury | Oct 27, 2015
Company News

Woodford mum on his GSK wish list

...the separation of the company's HIV business ViiV Healthcare, its consumer healthcare business and its Stiefel...
BioCentury | Oct 13, 2014
Clinical News

Arzerra ofatumumab: Phase III started

...GlaxoSmithKline's Stiefel dermatology business began the double-blind, placebo-controlled, international Phase III OPV116910 trial to compare 20...
BioCentury | May 26, 2014
Clinical News

Reasanz serelaxin regulatory update

...with Corthera Inc. In 2010, Novartis acquired Corthera, which had rights from Stiefel Laboratories Inc. GlaxoSmithKline acquired Stiefel...
Items per page:
1 - 10 of 93